Entering text into the input field will update the search result below

Circling Back On NuCana Stock

Mar. 03, 2021 3:44 PM ETNuCana plc (NCNA) Stock2 Comments


  • Today, we revisit a small oncology concern from across the pond named NuCana.
  • The company continues to advance a pipeline of improved versions of widely-prescribed chemotherapy agents.
  • A full analysis follows in the paragraphs below.
  • I do much more than just articles at The Busted IPO Forum: Members get access to model portfolios, regular updates, a chat room, and more. Get started today »

It was one of those perfect English autumnal days which occur more frequently in memory than in life.”― P.D. James, A Taste for Death

Back in late 2019, we took our first look at NuCana (NASDAQ:NCNA). We passed on making an investment recommendation for a sizable stake in this name until it raised additional capital and advanced its pipeline further. We did promise to revisit this intriguing concern in the future. Five quarters have passed since then, so it seems like it is time to peak back in on the company. An analysis follows below:

Company Overview:

NuCana is based in the U.K. and is a clinical stage biotech concern. The company is focused on developing treatment using its ProTide platform to transform common and widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer compounds.

Transforming Nucleoside Analogs into ProTides

Source: Company Presentation

The stock current trades just above $5.00 a share and remains deep in "Busted IPO" territory. The shares sport an approximate $275 million market capitalization.

Nucleoside Analogs: Flawed ProDrugs

Source: Company Presentation

The company has several compounds in development. The most advanced effort in the NuCana's pipeline centers around Acelarin. This is the company's improved version of Gemcitabine. This compound is used extensively and remains a backbone therapy in the standard of care for the treatment of many cancers, including biliary tract, pancreatic, ovarian, non-small cell lung, bladder and breast cancers according to the company's website. The company has investigated Acelarin against numerous cancers and this compound currently is currently undergoing a global Phase III registrational study to treat biliary tract cancer.

: Overview of Gemcitabine

Source: Company Presentation

There are currently no agents approved for the first-line treatment of biliary tract cancer but the current standard of care for advance stages of the disease is a combination of gemcitabine and cisplatin. More than 800 individuals across 15 countries

Author's note: I present and update my best small-cap Busted IPO stock ideas only to subscribers of my exclusive marketplace, The Busted IPO Forum. Our model portfolio has crushed the return of the Russell 2000 since its launch in the summer of 2017.  To join the Busted IPO Forum community, just click on the logo below.

This article was written by

Busted IPO Forum profile picture

The Busted IPO Forum is an investing group led by Bret Jensen, Chief Investment Strategist of Simplified Asset Management. Along with his team of analysts, Bret focuses on stocks that have been public for 18 months to 6 years, and that are significantly under their offering price.

The Busted IPO Forum: A model stock portfolio of attractive busted IPOs, trade alerts, deep dive analysis, a weekly option play idea and live chat.

Analyst’s Disclosure: I am/we are long NCNA. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I have a small watch item position in NCNA.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (2)

Yakimov profile picture
Just took a small position here. Just to keep my eye on NuCana. However I think there’s a strong potential here if managed properly and timed correctly. Definitely an interesting stock.
MikeFromNZ profile picture
Thanks Bret!
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About NCNA

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on NCNA

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.